What is Heart Failure? The Cardiovascular Epidemic of the 21st Century

The Pump, The Plumbing System & The Energy Supply

While new drugs for treating chronic heart failure continue to be approved, there has been no new therapy approved for acute heart failure in decades. ViCardia’s lead asset, GP531, addresses this major unmet medical need in a cost-effective manner–offering hope to 65 million patients worldwide. GP-531 is a first-in-class therapy that stimulates the mitochondria to produce more ATP, the chemical energy that powers all cellular functions. The lack of ATP in the heart muscle causes mechanical failure of the heart.